A Study of the Safety, Effectiveness and Maximum Tolerated Dose of Oral PQR309 for Patients with Advanced Solid Tumors

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety, effectiveness and the maximum tolerable dose of PQR309 for the treatment of selected patients who have advanced solid tumors with known activation of AKT/PI3K/mTOR.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of solid malignancy, for which no standard curative or life prolonging therapy is available
  • Age ≥ 18
  • ECOG Performance Status of ≤ 1
  • Males and females of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last investigational drug dose received
  • Life expectancy of ≥ 12 weeks
  • Signed informed consent

Exclusion Criteria

  • Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal, immunotherapy)
  • Major surgery within 14 days prior to starting study drug
  • Has poorly controlled diabetes mellitus, steroid-induced diabetes mellitus, or HbA1c > 7%
  • Is currently receiving warfarin for treatment, prophylaxis or otherwise
  • Has symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to enrolment, unstable angina pectoris, serious uncontrolled cardiac arrhythmia, symptomatic pericarditis, QTcB > 480 msec on the screening ECG
  • Pregnant or nursing (lactating)
  • Has any of the following mood disorders
    • Active major depressive episode
    • Bipolar disorder (I or II)
    • Obsessive-compulsive disorder
    • Schizophrenia
    • A history of suicidal attempt or ideation, or homicidal ideation
    • ≥ CTCAE Grade 3 anxiety
  • A history of interstitial pneumonitis or patients who require chronic oxygen

More information

Publicaciones

Publications are currently not available
.
CLS-20260200

Mayo Clinic Footer